|
1
|
Prantera C and Marconi S:
Glucocorticosteroids in the treatment of inflammatory bowel disease
and approaches to minimizing systemic activity. Therap Adv
Gastroenterol. 6:137–156. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cosnes J, Gower-Rousseau C, Seksik P and
Cortot A: Epidemiology and natural history of inflammatory bowel
diseases. Gastroenterology. 140:1785–1794. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Carter MJ, Lobo AJ and Travis SP: IBD
Section, British Society of Gastroenterology: Guidelines for the
management of inflammatory bowel disease in adults. Gut. 53(Suppl
5): V1–V16. 2004. View Article : Google Scholar
|
|
4
|
Podolsky DK: Inflammatory bowel disease. N
Engl J Med. 347:417–429. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Podolsky DK: The current future
understanding of inflammatory bowel disease. Best Pract Res Clin
Gastroenterol. 16:933–943. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Loftus EV Jr: Clinical epidemiology of
inflammatory bowel disease: Incidence, prevalence, and
environmental influences. Gastroenterology. 126:1504–1517. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Loftus EV Jr and Sandborn WJ: Epidemiology
of inflammatory bowel disease. Gastroenterol Clin North Am.
31:1–20. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Betteridge JD, Armbruster SP, Maydonovitch
C and Veerappan GR: Inflammatory bowel disease prevalence by age,
gender, race, and geographic location in the U.S. military health
care population. Inflamm Bowel Dis. 19:1421–1427. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yang SK, Loftus EV Jr and Sandborn WJ:
Epidemiology of inflammatory bowel disease in Asia. Inflamm Bowel
Dis. 7:260–270. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Goh K and Xiao SD: Inflammatory bowel
disease: A survey of the epidemiology in Asia. J Dig Dis. 10:1–6.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sands BE: New therapies for the treatment
of inflammatory bowel disease. Surg Clin North Am. 86:1045–1064.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sands BE: The risks and benefits of early
immunosuppression and biological therapy. Dig Dis. 30(Suppl 3):
100–106. 2012. View Article : Google Scholar
|
|
13
|
Prantera C, Pallone F, Brunetti G, Cottone
M and Miglioli M; The Italian IBD Study Group: Oral
5-aminosalicylic acid (Asacol) in the maintenance treatment of
Crohn's disease. Gastroenterology. 103:363–368. 1992.PubMed/NCBI
|
|
14
|
Lopez A, Billioud V, Peyrin-Biroulet C and
Peyrin-Biroulet L: Adherence to anti-TNF therapy in inflammatory
bowel diseases: A systematic review. Inflamm Bowel Dis.
19:1528–1533. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Danese S: Anti TNF-alpha treatment for
Crohn' disease: 'ménage a trois'. Curr Drug Targets. 11:136–137.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Danese S and Angelucci E: New and emerging
biologics in the treatment of inflammatory bowel disease: Quo
vadis? Gastroenterol Clin Biol. 33(Suppl 3): S217–S227. 2009.
View Article : Google Scholar
|
|
17
|
Danese S, Angelucci E, Malesci A and
Caprilli R: Biological agents for ulcerative colitis: Hypes and
hopes. Med Res Rev. 28:201–218. 2008. View Article : Google Scholar
|
|
18
|
Danese S, Colombel JF, Peyrin-Biroulet L,
Rutgeerts P and Reinisch W: Review article: The role of anti-TNF in
the management of ulcerative colitis - past, present and future.
Aliment Pharmacol Ther. 37:855–866. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Danese S, Colombel JF, Reinisch W and
Rutgeerts PJ: Review article: Infliximab for Crohn's disease
treatment - shifting therapeutic strategies after 10 years of
clinical experience. Aliment Pharmacol Ther. 33:857–869. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Danese S, Semeraro S, Armuzzi A, Papa A
and Gasbarrini A: Biological therapies for inflammatory bowel
disease: Research drives clinics. Mini Rev Med Chem. 6:771–784.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ota E, Takeiri M, Tachibana M, Ishikawa Y,
Umezawa K and Nishiyama S: Synthesis and biological evaluation of
molecular probes based on the 9-methylstreptimidone derivative
DTCM-glutarimide. Bioorg Med Chem Lett. 22:164–167. 2012.
View Article : Google Scholar
|
|
22
|
Shibasaki S, Yamashita K, Goto R, Wakayama
K, Tsunetoshi Y, Zaitsu M, Igarashi R, Haga S, Ozaki M, Umezawa K
and Todo S: Immunosuppressive effects of DTCM-G, a novel inhibitor
of the mTOR downstream signaling pathway. Transplantation.
95:542–550. 2013. View Article : Google Scholar
|
|
23
|
Funakoshi T, Yamashita K, Ichikawa N,
Fukai M, Suzuki T, Goto R, Oura T, Kobayashi N, Katsurada T,
Ichihara S, et al: A novel NF-κB inhibitor,
dehydroxymethylepoxyquinomicin, ameliorates inflammatory colonic
injury in mice. J Crohn's Colitis. 6:215–225. 2012. View Article : Google Scholar
|
|
24
|
El-Salhy M, Umezawa K, Gilja OH, Hatlebakk
JG, Gundersen D and Hausken T: Amelioration of severe TNBS induced
colitis by novel AP-1 and NF-κB inhibitors in rats.
ScientificWorldJournal. 2014:8138042014. View Article : Google Scholar
|
|
25
|
Elson CO, Sartor RB, Tennyson GS and
Riddell RH: Experimental models of inflammatory bowel disease.
Gastroenterology. 109:1344–1367. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Matsumoto N, Ariga A, To-e S, Nakamura H,
Agata N, Hirano S, Inoue J and Umezawa K: Synthesis of NF-kappaB
activation inhibitors derived from epoxyquinomicin C. Bioorg Med
Chem Lett. 10:865–869. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Grimstad T, Bjørndal B, Cacabelos D,
Aasprong OG, Omdal R, Svardal A, Bohov P, Pamplona R, Portero-Otin
M, Berge RK and Hausken T: A salmon peptide diet alleviates
experimental colitis as compared with fish oil. J Nutr Sci.
2:e22013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Stucchi AF, Shofer S, Leeman S, Materne O,
Beer E, McClung J, Shebani K, Moore F, O'Brien M and Becker JM:
NK-1 antagonist reduces colonic inflammation and oxidative stress
in dextran sulfate-induced colitis in rats. Am J Physiol
Gastrointest Liver Physiol. 279:G1298–G1306. 2000.PubMed/NCBI
|
|
29
|
Cooper HS, Murthy SN, Shah RS and
Sedergran DJ: Clinicopathologic study of dextran sulfate sodium
experimental murine colitis. Lab Invest. 69:238–249.
1993.PubMed/NCBI
|
|
30
|
Mao JW, Huang YS, Tang HY, Bi J, Liu YF
and Wang YD: Flt3/Flt3L participates in the process of regulating
dendritic cells and regulatory T cells in DSS-induced colitis.
Gastroenterol Res Pract. 2014:4835782014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Dieleman LA, Palmen MJ, Akol H, Bloemena
E, Peña AS, Meuwissen SG and Van Rees EP: Chronic experimental
colitis induced by dextran sulphate sodium (DSS) is characterized
by Th1 and Th2 cytokines. Clin Exp Immunol. 114:385–391. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Low D, Nguyen DD and Mizoguchi E: Animal
models of ulcerative colitis and their application in drug
research. Drug Des Devel Ther. 7:1341–1357. 2013.PubMed/NCBI
|
|
33
|
Takeiri M, Tachibana M, Kaneda A, Ito A,
Ishikawa Y, Nishiyama S, Goto R, Yamashita K, Shibasaki S, Hirokata
G, et al: Inhibition of macrophage activation and suppression of
graft rejection by DTCM-glutarimide, a novel piperidine derived
from the antibiotic 9-methylstreptimidone. Inflamm Res. 60:879–888.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Umezawa K: Possible role of peritoneal
NF-κB in peripheral inflammation and cancer: Lessons from the
inhibitor DHMEQ. Biomed Pharmacother. 65:252–259. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yamamoto M, Horie R, Takeiri M, Kozawa I
and Umezawa K: Inactivation of NF-kappaB components by covalent
binding of (−)-dehydroxymethylepoxyquinomicin to specific cysteine
residues. J Med Chem. 51:5780–5788. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ariga A, Namekawa J, Matsumoto N, Inoue J
and Umezawa K: Inhibition of tumor necrosis factor-alpha-induced
nuclear translocation and activation of NF-kappa B by
dehydroxymethy-lepoxyquinomicin. J Biol Chem. 277:24625–24630.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Schonthaler HB, Guinea-Viniegra J and
Wagner EF: Targeting inflammation by modulating the Jun/AP-1
pathway. Ann Rheum Dis. 70(Suppl 1): i109–i112. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Matsushima A, Kaisho T, Rennert PD, Nakano
H, Kurosawa K, Uchida D, Takeda K, Akira S and Matsumoto M:
Essential role of nuclear factor (NF)-kappaB-inducing kinase and
inhibitor of kappaB (IkappaB) kinase alpha in NF-kappaB activation
through lymphotoxin beta receptor, but not through tumor necrosis
factor receptor I. J Exp Med. 193:631–636. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Umezawa K, Ariga A and Matsumoto N:
Naturally occurring and synthetic inhibitors of NF-kappaB
functions. Anticancer Drug Des. 15:239–244. 2000.
|
|
40
|
Brassesco MS, Roberto GM, Morales AG,
Oliveira JC, Delsin LE, Pezuk JA, Valera ET, Carlotti CG Jr, Rego
EM, de Oliveira HF, et al: Inhibition of NF-κB by
dehydroxymethylepoxyquinomicin suppresses invasion and
synergistically potentiates temozolomide and γ-radiation
cytotoxicity in glioblastoma cells. Chemother Res Pract.
2013:5930202013.
|
|
41
|
Celegato M, Borghese C, Umezawa K,
Casagrande N, Colombatti A, Carbone A and Aldinucci D: The NF-κB
inhibitor DHMEQ decreases survival factors, overcomes the
protective activity of microenvironment and synergizes with
chemotherapy agents in classical Hodgkin lymphoma. Cancer Lett.
349:26–34. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Fukushima T, Kawaguchi M, Yorita K, Tanaka
H, Takeshima H, Umezawa K and Kataoka H: Antitumor effect of
dehydroxymethylepoxyquinomicin, a small molecule inhibitor of
nuclear factor-κB, on glioblastoma. Neurooncol. 14:19–28. 2012.
|
|
43
|
Kozakai N, Kikuchi E, Hasegawa M, Suzuki
E, Ide H, Miyajima A, Horiguchi Y, Nakashima J, Umezawa K,
Shigematsu N and Oya M: Enhancement of radiosensitivity by a unique
novel NF-κB inhibitor, DHMEQ, in prostate cancer. Br J Cancer.
107:652–657. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Lampiasi N, Azzolina A, Umezawa K,
Montalto G, McCubrey JA and Cervello M: The novel NF-κB inhibitor
DHMEQ synergizes with celecoxib to exert antitumor effects on human
liver cancer cells by a ROS-dependent mechanism. Cancer Lett.
322:35–44. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Lampiasi N, Umezawa K, Montalto G and
Cervello M: Poly (ADP-ribose) polymerase inhibition synergizes with
the NF-κB inhibitor DHMEQ to kill hepatocellular carcinoma cells.
Biochim Biophys Acta. 1843:2662–2673. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Miyanishi N, Suzuki Y, Simizu S, Kuwabara
Y, Banno K and Umezawa K: Involvement of autocrine CXCL12/CXCR4
system in the regulation of ovarian carcinoma cell invasion.
Biochem Biophys Res Commun. 403:154–159. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Mino K, Ozaki M, Nakanishi K, Haga S, Sato
M, Kina M, Takahashi M, Takahashi N, Kataoka A, Yanagihara K, et
al: Inhibition of nuclear factor-kappaB suppresses peritoneal
dissemination of gastric cancer by blocking cancer cell adhesion.
Cancer Sci. 102:1052–1058. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Suzuki K, Aiura K, Matsuda S, Itano O,
Takeuchi O, Umezawa K and Kitagawa Y: Combined effect of
dehydroxymethylepoxyquinomicin and gemcitabine in a mouse model of
liver metastasis of pancreatic cancer. Clin Exp Metastasis.
30:381–392. 2013. View Article : Google Scholar
|
|
49
|
Yasuda A, Kondo S, Nagumo T, Tsukamoto H,
Mukudai Y, Umezawa K and Shintani S: Anti-tumor activity of
dehydroxymethylepoxyquinomicin against human oral squamous cell
carcinoma cell lines in vitro and in vivo. Oral Oncol. 47:334–339.
2011. View Article : Google Scholar : PubMed/NCBI
|
